Companion Diagnostics( CDx) Market size is expected to reach US $ 5.0 Billion by 2024, growing at a CAGR of 12.0 % from 2016 to 2024
The global companion diagnostics( CDx) market was valued at US $ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0 % during the forecast period 2016 to 2024
Companion diagnostic( CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying genetic mutations and the health and treatment approach implications. In July 2016, the U. S. FDA released a draft guideline for development of a therapeutic product accompanying an IVD companion diagnostic. Companion diagnostics include Gleevec( imatinib